Mineralys Therapeutics Inc (MLYS) Stock Price, Quote & News

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 378 6240

Website: mineralystx.com

Address:

150 N. Radnor Chester Rd., Suite F200, Radnor, United States

CrispDry Jan. 7 at 7:36 PM

$MLYS taking advantage of the flat trading and building a position

0 · Reply

Jakeipedia Jan. 6 at 3:23 PM

$MLYS very excited for this stock and 2026. Let’s go

0 · Reply

OptionRunners Dec. 29 at 2:37 PM

$MLYS those were closed out on Friday. OI dropped in all 3 strikes. Still a lot sitting in them though.

0 · Reply

OptionRunners Dec. 26 at 7:55 PM

$MLYS seems like some of these may have gotten closed out this morning. 5,083 of the 40/30/60 spreads for $3.25. But need to see the OI to confirm.

0 · Reply

ZacksResearch Dec. 24 at 6:09 PM

Biotech momentum is BACK — and these names are already up big 👀🚀 $MLYS, $LYEL, $NKTR and $INSM are all up more than 50% in 2025, powered by clinical wins, FDA approvals, and M&A deals that are reviving confidence across the drug and biotech space heading into 2026. See why these high-flyers may still have room to grow 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-teaser-26257&ADID=SYND_STOCKTWITS_TWEET_2_2808693_TEASER_26257

0 · Reply

ZacksResearch Dec. 24 at 5:09 PM

$MLYS skyrocketed 203.4% YTD — is there more fuel in the tank? 🚀 Lorundrostat hit primary endpoints in key studies and an NDA is set for early 2026. With a Zacks Rank #2 (Buy), the setup looks promising for a continued run. Explore the full potential here 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-body-26256&ADID=SYND_STOCKTWITS_TWEET_2_2808693_BODY_26256

0 · Reply

Quantumup Dec. 19 at 4:09 PM

BofA⬆️ $MLYS's PT to $46 from $43/reiterated at Buy. $AZN $ALNY - $RHHBY $NVS Stifel⬆️PT to $52 from $45 and reiterated at Buy. Here's what Stifel had to say in its note: https://x.com/Quantumup1/status/2002047867654136129?s=20

0 · Reply

IN0V8 Dec. 19 at 3:41 PM

$MLYS Buy BofA Global Research raises PT to $46 from $43 Stifel raises target price to $52 from $45

0 · Reply

JarvisFlow Dec. 19 at 2:45 PM

Stifel has updated their rating for Mineralys Therapeutics ( $MLYS ) to Buy with a price target of 52.

0 · Reply

YEHMINGZHU Dec. 13 at 7:20 PM

$MLYS Lorundorestat is a highly selective Aldosterone Synthase Inhibitor (ASI). It works by targeting the over-production of aldosterone, a hormone that drives high blood pressure in many patients resistant to standard therapies. This trial's results were so impactful they were recognized in the Journal of the American Medical Association (JAMA) "Research of the Year" Roundup. I will be looking for an entry here as I believe it is de risked now. Data anticipated Q1 2026 and this drug is the only one being studied to address OSA. This is there opportunity to turn into a platform therapy. Can break above $50 or $60 on this readout. **No position yet**

0 · Reply

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Dec 28, 2025, 8:03 AM EST - 10 days ago

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026

Dec 12, 2025, 11:00 AM EST - 26 days ago

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Nov 26, 2025, 4:05 PM EST - 6 weeks ago

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 7:11 PM EST - 2 months ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 2 months ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 6:10 PM EST - 2 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Oct 21, 2025, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Oct 1, 2025, 3:17 PM EDT - 3 months ago

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions

Sep 30, 2025, 8:00 AM EDT - 3 months ago

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Sep 19, 2025, 12:53 PM EDT - 3 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY SNDX TVTX

Sep 5, 2025, 9:00 AM EDT - 4 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 4, 2025, 4:01 PM EDT - 4 months ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 3, 2025, 8:17 AM EDT - 4 months ago

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BRKR

Sep 2, 2025, 9:33 PM EDT - 4 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 4 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Aug 13, 2025, 12:16 AM EDT - 5 months ago

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 4:05 PM EDT - 5 months ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Jun 30, 2025, 11:17 AM EDT - 6 months ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 17, 2025, 9:57 AM EDT - 7 months ago

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Jun 17, 2025, 7:00 AM EDT - 7 months ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

May 24, 2025, 4:30 AM EDT - 8 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 20, 2025, 8:00 AM EDT - 8 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 12, 2025, 8:20 PM EDT - 8 months ago

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:05 PM EDT - 8 months ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 8:00 AM EDT - 8 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2025, 4:05 PM EDT - 8 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Apr 23, 2025, 5:23 PM EDT - 9 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mar 29, 2025, 2:30 PM EDT - 10 months ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 25, 2025, 8:00 AM EDT - 10 months ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 18, 2025, 4:01 PM EDT - 10 months ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 17, 2025, 8:00 AM EDT - 10 months ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 12, 2025, 8:36 AM EDT - 10 months ago

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

LDI MOMO

Mar 11, 2025, 10:20 PM EDT - 10 months ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 10, 2025, 6:25 PM EDT - 10 months ago

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mar 10, 2025, 1:50 PM EDT - 10 months ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mar 10, 2025, 1:09 PM EDT - 10 months ago

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mar 10, 2025, 7:12 AM EDT - 10 months ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:00 AM EDT - 10 months ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 7, 2025, 4:01 PM EST - 10 months ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Feb 12, 2025, 1:38 PM EST - 11 months ago

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 11 months ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 5, 2025, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Jan 19, 2025, 8:18 PM EST - 1 year ago

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Nov 11, 2024, 10:00 PM EST - 1 year ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

CrispDry Jan. 7 at 7:36 PM

$MLYS taking advantage of the flat trading and building a position

0 · Reply

Jakeipedia Jan. 6 at 3:23 PM

$MLYS very excited for this stock and 2026. Let’s go

0 · Reply

OptionRunners Dec. 29 at 2:37 PM

$MLYS those were closed out on Friday. OI dropped in all 3 strikes. Still a lot sitting in them though.

0 · Reply

OptionRunners Dec. 26 at 7:55 PM

$MLYS seems like some of these may have gotten closed out this morning. 5,083 of the 40/30/60 spreads for $3.25. But need to see the OI to confirm.

0 · Reply

ZacksResearch Dec. 24 at 6:09 PM

0 · Reply

ZacksResearch Dec. 24 at 5:09 PM

0 · Reply

Quantumup Dec. 19 at 4:09 PM

0 · Reply

IN0V8 Dec. 19 at 3:41 PM

$MLYS Buy BofA Global Research raises PT to $46 from $43 Stifel raises target price to $52 from $45

0 · Reply

JarvisFlow Dec. 19 at 2:45 PM

Stifel has updated their rating for Mineralys Therapeutics ( $MLYS ) to Buy with a price target of 52.

0 · Reply

YEHMINGZHU Dec. 13 at 7:20 PM

0 · Reply

BillionerOfKing Dec. 11 at 1:12 AM

$MLYS Current Stock Price: $36.17 Contracts to trade: $35 MLYS Dec 19 2025 Call Entry: $0.40 Exit: $0.79 ROI: 99% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OptionRunners Dec. 10 at 9:23 PM

$MLYS these got added again into the close. Total of 14,567 contracts today.

0 · Reply

OptionRunners Dec. 10 at 7:37 PM

$MLYS again .. 35/30/60 this time

0 · Reply

OptionRunners Dec. 9 at 7:32 PM

$MLYS bear seagulls got added to again here. Originally on 12/3 for $3.35 and now up to $4.44.

0 · Reply

OptionRunners Dec. 5 at 8:15 PM

$MLYS these got added to again earlier. The $40's (long leg) are ITM

0 · Reply

OptionRunners Dec. 3 at 4:10 PM

$MLYS buyer of the March 20th 2026 $40/$30/$60 bear seagulls 3,500 times for $3.35

0 · Reply

Uneducated_Trader Nov. 17 at 5:36 PM

$MLYS bought last week. Thank you mlys

0 · Reply

medguy Nov. 14 at 4:24 PM

$MLYS and $DGNX looking for reversal

0 · Reply

Arcides Nov. 14 at 3:09 PM

$MLYS standed good yesterday but today is falling on high volume.

0 · Reply

www_larval_com Nov. 14 at 2:42 PM

$SGML 17%[10%] $CMBM 12%[16%] $MLYS 9%[-12%] $AVXL 9%[-34%] $TSSI -8%[-41%] most notable movement within the first minutes of trading.

0 · Reply

JarvisFlow Nov. 12 at 11:46 AM

HC Wainwright & Co. updates rating for Mineralys Therapeutics ( $MLYS ) to Buy, target set at 52 → 56.

0 · Reply

JarvisFlow Nov. 11 at 2:27 PM

Wells Fargo has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Overweight with a target price of 50 → 55.

0 · Reply

Market Cap	2.83B
Revenue (ttm)	0.00
Net Income (ttm)	-177.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,465,700
Avg Vol	1,568,192
Day's Range	N/A - N/A
Shares Out	79.14M
Stochastic %K	32%
Beta	0.49
Analysts	Strong Sell
Price Target	$50.88